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ABSTRACT
Severe depression is one of the most common 
psychological disabilities, with a global point prevalence 
of 4.7%. The World Health Organisation predicts it to be 
the leading cause of disease burden by 2030. With 350 
million depressed people, depression is a debilitating 
condition where only a third of treated patients achieve 
remission after the first antidepressant treatment. Up 
to 34% of the patients are treatment resistant, whereas 
another 15% respond partially, following standard 
doses of antidepressants for 6 weeks or more. Failure 
to respond to two consecutive antidepressants leads to 
greater reductions in remission rates. 
Recurrence rates, despite specialised care, are 60% 
and 85% after 5 and 15 years post-recovery respectively. 
Inadequate efficacy, adverse effects, and sensitivity to 
current treatments call for more effective and tolerable 
treatment options. With over 20 years of research, 
repetitive transcranial magnetic stimulation (rTMS) is 
a non-invasive treatment that alters brain activity and 
cortical excitability permanently, making it an effective 
antidepressant treatment beyond the conventional ones, 
including electroconvulsive therapy (ECT) in some 
studies. 
Furthermore, rTMS is safe, natural, painless, fast 
acting and approved by the Food and Drug Administration 
(FDA) and the National Institute for Health and Care 
Excellence (NICE). It has virtually no side effects 
and only one absolute contraindication (epilepsy). 
Experience of its use in Malta has shown improvement in 
diminishing the key symptoms of depression, decreased 
suicidal ideation and a decrease in other psychiatric 
and neurological symptoms within hours of the first 
sessions. Besides providing immediate relief and hope 
for patients and relatives, this improvement has many 
clinical and future management implications. Research 
is now underway to apply this novel technology and its 
variants to other physical and psychological disorders. 
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BASIC PRINCIPLES AND HISTORY
Repetitive transcranial magnetic stimulation (rTMS) is a 
safe, painless, effective, natural, evidence-based treatment 
for patients suffering from severe unipolar affective 
disorder/depression who are treatment resistant and/
or treatment intolerant, i.e. they are generally labelled 
as suffering from treatment-resistant severe/major 
depression (TRD) (Carpenter et al., 2012; Connolly et 
al., 2012). Others find rTMS appealing as they may be 
sceptical of conventional treatment. 
Revolutionary in its approach to treating TRD, rTMS 
is the brainchild of Baker and his colleagues who have 
been experimenting with single pulse TMS in Sheffield, 
UK since the 1980s (Hotlzheimer and Mc Donald, 
2014).  The UK team pioneered stimulating the human 
brain’s cortex after being inspired by Galvani and 
Aldini’s eighteenth century experiments on electrically 
stimulating the peripheral muscles of dead animals and 
humans respectively.  Their objective at the time was to 
map the cortex and elicit a corresponding short-lived 
motor stimulation of peripheral muscles (Baker, Jalinous 
and Freeston, 1985). Technological developments 
subsequently produced repetitive pulse TMS which was 
shown to have long lasting effects on the cortex that 
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persisted beyond the stimulus delivery (Pascual-Leone 
et al., 1996; Maeda et al., 2000).
This non-invasive and novel treatment is based on 
the discoveries of British nineteenth century physicist 
Michael Farady, whose Law of Electromagnetic Induction 
predicts how a changing magnetic field will interact 
with an electric circuit to produce an electromotive 
force - a phenomenon called electromagnetic induction. 
In essence, exposing a conductor to a rapidly changing 
magnetic field will induce a current in the conductor. 
rTMS works by inducing a rapidly changing magnetic 
field in a “depression sensitive” brain/cortical area, which 
is populated by neurons and is located just under the 
skull. This rapidly changing field induces a current in the 
neurons (the conductor). Hence, the area is stimulated 
to be more electrically active.
To achieve this, TMS devices consist of a large 
capacitor, a control mechanism that enables the capacitor 
to be rapidly discharged, and a conductive coil through 
which the current travels to generate a powerful and 
fluctuating magnetic field (Barker, 1999). Through the 
process of electromagnetic induction described above, 
this rapid pulse of electric current induces a rapidly 
fluctuating magnetic field, which in turn induces an 
electric current in the underlying brain neurons (Wagner, 
Valero-Cabre and Pascual-Leone, 2007).  How much 
brain tissue is stimulated is dependent on the shape of 
the coil as well as the intensity of the stimulation i.e. 
amount of current discharged by the machine (Pascual-
Leone et al., 2002). 
In biophysiological terms, several studies concerning 
depression show that the left dorso-lateral pre-frontal 
cortex (LDLPFC), along with deeper cortical structures 
such as the limbic system, are associated with mood 
regulation. Hence the LDLPFC is a lynchpin in the 
pathogeneses of an affective illness. Overall, a depressed 
patient’s brain is less active than a healthy brain, as 
evidenced by several neuroimaging studies. One study 
in particular demonstrates that depressed patients have 
fewer brain receptors, less circulating neurotransmitters 
(e.g. serotonin) and fewer healthy synaptic connections 
between neurons (Psych Central, 2008).  
rTMS addresses this neuronal “apathy” (or 
hypoactivity) by progressively re-stimulating a current in 
the LDLPFC neurons (i.e. a wave of depolarisation down 
the neuron membranes), so as to eventually restore the 
balance of neurotransmitters and healthy nerve contacts 
with each other. The postulated principle which keeps 
neurons healthy, active and interconnected is based 
on the principle of Hebbian neuroplasticity (i.e. the 
development of new specialised neural networks, which 
allows for sustained improvement over time). Hebbian 
neuroplasticity resembles the long term potentiation 
(LTP) or long term depression (LTD) of neurons. LTP 
implies an increase in the development of synaptic 
transmission of neurotransmitters, which induces a wave 
of depolarisation along the neuronal membrane. This 
depolarisation is thus the generated current running 
down the neuron. The opposite of LTP is LTD, which 
produces a long lasting decrease in synaptic activity.
The positive behavioural effects of this technology 
persist after a course of rTMS treatment through 
neuroplasticity (Christyakov et al., 2010). Bickford 
and his colleagues first extended the domain of TMS 
research into neuropsychiatry in 1987. Transient mood 
elevation in healthy subjects receiving single-pulse 
stimulations to the motor cortex was described (Bickford 
et al., 1987). This triggered the scientific investigation 
of the effects of depolarising magnetic fields in a variety 
of neuropsychiatric disorders. The clinical utility 
breakthrough came in 2008 to treat patients suffering 
from severe depression, who had not responded to at least 
one antidepressant in their current episode (i.e. they were 
deemed to be treatment-resistant or intolerant according 
to FDA criteria) (Herwig et al., 2007; O’Reardon et al., 
2007; George et al., 2010). The LDLPFC was targeted 
with very positive outcomes.
EXPERIMENTAL AND THERAPEUTIC 
FUNCTIONS - THE E/I RATIO
rTMS is used both experimentally and therapeutically. 
In the experimental domain TMS can be applied in single 
pulses to depolarize a small population of neurons in a 
targeted brain region. Cortical motor outputs can thus 
be mapped, central motor conduction times can be 
assessed and the cortical silent period can be measured 
(a measure of intracortical inhibition). These parameters 
may be affected by pathologies of the central nervous 
system such as autism (Kobayashi and Pascual-Leone, 
2003). Therapeutically, trains of rTMS pulses can be 
applied at various stimulation frequencies and patterns 
to modulate local cortical excitability beyond the duration 
of the stimulation itself. Depending on the parameters 
of stimulation, the excitability can be either facilitated 
or suppressed (Pascual-Leone et al., 1994). The after-
effects of rTMS are thought to be related to changes in 
efficacy (in either the positive or negative direction) of 
synaptic connections of the neurons being stimulated 
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(Hoogendam, Ramakers and Di Lazzaro, 2010). These 
after-effects have thus been used to study cortical 
plasticity mechanisms in a number of populations 
(Pascual-Leone et al., 2011).
rTMS has the potential to detect and define the 
Excitatory/Inhibitory (E/I) ratio for a particular disorder. 
E/I ratios are a measure of the activity-dependent neural 
feedback systems that tightly control network excitability. 
Thought to be crucial for proper brain development, 
the relative degree of excitatory and inhibitory drive in 
a neural circuit reflects a form of homeostatic plasticity 
that helps to maintain neuronal activity within a narrow, 
safe range. Processing of neural information is thought to 
occur by integration of excitatory and inhibitory synaptic 
inputs. As such, precise control mechanisms must exist 
to maintain an appropriate balance between each synapse 
Clinically, there is much research for various 
neurological and psychiatric conditions. The list 
continues to grow as researchers alter the neurostimulator 
settings, type of magnetic field, and the cortical area to 
be stimulated (see Table1). 
EFFICACY
While ant idepressants,  psychotherapies and 
electroconvulsive therapy (ECT) are effective in treating 
depression, a substantial proportion of patients fail 
to respond to these treatment regimens and hence 
are known as treatment-resistant depression (TRD) 
patients. TRD is estimated to occur in around 50 to 
60% of all patients (i.e. 5 out of 100 people in the 
general healthy population) (Fava and Davidson, 1996). 
Despite providing relief to a proportion of patients, other 
interventions bear weak or inconsistent evidence for 
routine clinical recommendation.
Table 2 summarises the various characteristics 
of the routine, evidence-based available treatments 
for TRD compared to rTMS. The evidence base for 
psychological and other therapies is variable or 
incomplete. This is due to many factors including 
the heterogeneous therapies available, lack of 
standardised data and sample populations, study 
design, and funding. This does not mean, however, 
that such therapies do not have an important role 
to play in the management of depression. The most 
widely researched therapies to date are CBT and 
mindfulness-based therapies.
rTMS does not require hospital admission or 
anaesthesia, unlike another more commonly used 
form of brain stimulation namely electroconvulsive 
therapy (ECT) (Cusin and Dougherty, 2012). Apart 
from the potential anaesthetic complications (e.g. 
nausea and heart problems), ECT is known to 
cause deficiencies with respect to remembering 
facts and with learning new material, as well as 
inducing post ictal confusion and muscle aches, 
among others. Many researchers argue that rTMS 
is poised to dethrone ECT as the ‘gold standard’ 
treatment for TRD.
TREATMENT RESISTANT DEPRESSION 
PROTOCOL, FDA AND NICE APPROVAL
A specific protocol defining the dose and frequency of 
the magnetic pulses delivered by rTMS has been widely 
studied for TRD. This protocol has been used in several 
countries after approval was granted by the American 
FDA (FDA Approval K061053) (Horvath et al., 2010). 
Table 1: Some neurological and psychiatric disorders where 
rTMS is being applied
Anorexia nervosa 
Autism
Bipolar affective disorder
Cocaine dependence
Depersonalisation Disorder
Fibromyalgia
Migraine
Neuropathic pain
Obsessive Compulsive Disorder (OCD)
Parkinson’s disease 
Post Traumatic Stress Disorder (PTSD)
Stroke 
Suicidal ideation (rapidly reduced with rTMS)
Tinnitus
type. Altered E/I ratios are noted in neuropsychiatric 
disorders including depression, Obsessive Compulsive 
Disorder (OCD), schizophrenia, epilepsy and autism.
As E/I ratios are specific for a disorder, they may thus 
provide a screening/confirmatory test for physical and 
psychological conditions which are difficult to detect 
clinically. rTMS can then be used therapeutically for these 
disorders as it alters the relative excitability and inhibition 
(E/I ratio) in targeted circuits to restore these networks 
to a healthy baseline. 
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Table 2: Characteristics of routine, evidence-based available treatments for TRD compared to rTMS
Antidepressants eCt
Psychological / 
other therapies
rtMs
effectiveness
28 - 59% 
(Geddes et al., 2003; 
Sinyor, Schaffer & Levitt, 
2010)
60 - 80% 
(Geddes et al., 2003)
Comparable to 
medication?
Comparable to ECT 
or better (O’Connor 
et al., 2003; Schulze-
Rauschenbach, 2005; 
Rosa et al., 2006)
Beginning 
of therapeutic 
effect
4 - 6 weeks 1 week Weeks  <1 week
Common 
side effects
Headache;
Dry mouth;
Dizziness;
Constipation;
Nausea;
Blurred vision; 
Urinary retention;
Sexual issues
Loss of memory; 
Muscular pain; Nausea;
Headache
Stress which may cause 
symptom exacerbation:
Emotional turmoil;
Higher expressed 
emotions in families
Self limiting mild 
headache or resolves 
with a single dose of 
paracetamol
incidence 
of side effects
Up to 86% will 
experience at least one 
significant adverse event 
(Hu et al., 2004); 
Up to 34% will 
experience secondary 
sexual dysfunction due 
to medication 
(Hu et al., 2004)
29 - 55% 
(Rose et al., 2003)
Unknown
Up to 20%
(Carpenter, 2005)
rTMS was also approved by other countries, including 
by NICE in the U.K. in 2015 (IPG542) (NICE, 2015). 
Moreover, it has been suggested that the clinical 
effectiveness could be improved by developing further 
novel protocols and identifying local brain regions 
using neuro-navigation to improve the targeted pulse 
delivery (Fitzgerald et al., 2009; Fox et al., 2012).  Hybrid 
protocols are also being devised to reduce the duration of 
the session, while maximising the efficacy of treatment. 
These protocols also include adding standard treatments 
to achieve remission faster.
ADMINISTERING rTMS
After an initial assessment and after obtaining consent, 
rTMS treatment is administered by sitting in a comfortable, 
reclining airline-like chair (Figure 1). The treatment coil 
is placed on the scalp over the LDLPFC, as shown in 
Figure 2. The patient then receives a sequence of several 
short “trains” (or pulses) of stimulation for up to 40 
minutes. Throughout the entire procedure, the patient 
remains awake and alert. He can read a magazine, watch 
TV or even undergo psychological therapy during the 
session. No extra medication is administered. Clinical 
experience has shown that patients often need less regular 
medication as they improve with rTMS, as endorsed by 
NICE in 2015. 
ADVANTAGES, SAFETY 
AND SIDE-EFFECTS OF rTMS
rTMS has a number of advantages over other 
treatments as listed below:
•	 Natural, evidence-based, non-invasive, localised, 
and harmless treatment.
•	 No debilitating side effects related to pills or 
psychotherapy.
•	 No anaesthesia required (i.e. it is non-systemic).
•	 rTMS is an outpatient treatment, with no 
restriction of daily activities.
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•	 The patient remains awake (can talk, listen to 
music, etc).
•	 Rapid improvement in the patient’s symptoms 
(3 – 7 days for depression).
•	 No adverse side effects in the vast majority 
of patients.
•	 Reduce need for regular medication.
•	 Can be used concurrently with medication/
psychological therapies.
rTMS is now widely used and has been approved by 
major centres worldwide (including Mayo Clinic, Johns 
Hopkins, Yale, Nottinghamshire NHS Trust, New South 
Wales University, and Sydney University). Butler Hospital 
in Providence, Rhode Island, USA is one such centre of 
excellence and a pioneer in the field. Headed by world expert 
Professor Linda Carpenter, Butler Hospital has conducted 
more than 10,000 active treatments to date without adverse 
outcomes or severe side effects (Carpenter, 2015).
The most frequently experienced side effect of rTMS is a 
mild headache that responds to a low dose of paracetamol. 
This is reported in only about 1 in 10 patients. Headaches 
tend to diminish over the course of treatment, although 
adjustments can be made immediately in coil positioning 
and stimulation settings to remove the discomfort. To date, 
no single serious side effect has been encountered in the 
local cohort, ever since the start of rTMS treatments in 2016.
Seizures are a theoretical possibility and hence the only 
absolute contraindication for TMS is a history of active 
epilepsy. However, less than 20 cases of TMS induced 
seizures have been reported out of more than 10, 000 
subjects in the past 25 years. To put this in perspective, 
the risk of a seizure is much more likely to occur by 
ingesting co-amoxyclav. In other words, this minute risk 
is considered to be less than 0.01% (Rossi et al., 2009). 
In summary, the established benefits of treatment by 
far outweigh the probability of side effects.
 rTMS IN PREGNANCY AND IN CHILDREN
So far, there is no long term safety data available on 
pregnancy, nursing women or children. A recent study 
has demonstrated that rTMS can be used effectively in 
pregnant patients (Kim et al., 2015). Studies are ongoing 
on the use of rTMS in children. More research is however 
needed to address the safety and efficacy of rTMS in these 
special populations.
PROMISING FUTURE STIMULATION 
THERAPIES
Other treatments like direct current stimulation, vagal nerve 
stimulation, and deep brain stimulation are also being 
actively investigated and researched. Deep brain stimulation 
in particular, which uses an H-shaped coil as opposed to 
a standard figure of eight coil, is emerging as a promising 
“close second” to rTMS. This was indicated in a recent 
multi-centre randomised control study, which concluded 
that the effects appear “durable”, and a “clinically significant 
improvement” was seen in patients resistant to multiple 
antidepressants (Levkovitz et al., 2015). A further recent 
analysis corroborated these findings (Hardy et al., 2016).
Figure 1: An image showing the set up of an rTMS Clinic in Malta
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INTERMITTENT THETA BURST STIMULATION 
A recent protocol has been devised as a variant of rTMS 
for TRD. This protocol, now available locally, delivers 
theta waves in ‘bursts’ to the brain, hence the term 
‘intermittent theta burst stimulation’ (iTBS). Theta waves 
are naturally present over the cortex and hippocampus 
and are readily detectable by electroencephalography 
(EEG). In the right concentration and location, these 
waves are associated with healthy cognitive function, 
levels of alertness, and mood (Lega, Jacobs & Kahana, 
2012).
The principle of electromagnetic induction also 
applies here in order to revive the depressed person’s 
brain (Chung, Hoy & Fitzgerald, 2014). Being similar to 
classic rTMS in terms of administration and preparation, 
preliminary data shows that iTBS has a similar efficacy 
and side effect profile. The huge advantage of iTBS over 
rTMS is that the treatment session only lasts 3 minutes. 
TRANSCRANIAL DIRECT 
CURRENT STIMULATION
This technology is easy to use and can be used at home 
or at work. Transcranial direct current stimulation (tDCS) 
is a non-invasive method of electrical stimulation of the 
brain using a weak direct current applied to the scalp 
through electrodes to treat TRD (Loo et al., 2012). The 
aim is to modify cortical excitability and activity in the 
brain areas under the scalp electrodes. It is thought to 
work through the depolarisation and hyperpolarisation 
of cortical neurons. The patient, who remains awake 
and alert during the procedure, is usually seated, while 
a portable battery-operated stimulator delivers a constant 
low-strength direct current to two saline-soaked sponge 
electrodes placed on the scalp. Data on this technology is 
still inconsistent in terms of efficacy, and scalp burns have 
been reported. Another concern is that self-medication 
without professional supervision is a strong possibility. 
The advantage of tDCS is that it can be used in the privacy 
of one’s own home.
rTMS – THE EXPERIENCE IN MALTA
Crisis Resolution Malta was the first to offer rTMS in Malta 
to the public since early 2016, having conducted over 
1000 sessions so far. Patients have different expectations 
and fears, hence the need for accurate, evidence-based 
and patient explanation of the technology. A lot of 
these fears stem from the novelty and from inaccurate 
or outdated information on the web. The majority of 
patients (approximately 70%) improve within a few hours 
of a single treatment. They may feel somewhat ‘lighter’ in 
mood and/or experience better quality sleep. They also 
tend to feel more refreshed in the morning.
Importantly, suicidal ideation is also markedly 
reduced after a single session, making the difference 
between immediate hospitalisation versus supervised 
discharge home. The implications of the latter cases 
are significant in many ways from a social, clinical and 
economic standpoint, among others. On the latter point, 
there is also potential in rTMS being routinely used by 
crisis teams. The burden of symptoms in disorders such 
as post-traumatic stress disorder, obsessive–compulsive 
disorder (OCD), cocaine dependence and autism are 
also being reduced. Furthermore, patients have not yet 
experienced significant side effects.
iTBS has also been carefully introduced with 
somewhat promising results for other disorders including 
OCD, eating disorders, cocaine abuse and neuropathic 
pain. tDCS is now also available under supervision.
CONCLUSION
rTMS and its variants are safe, effective, evidence-
based and natural electromagnetic stimulation 
treatments which have growing applications in 
physical and psychological health. They provide an 
appealing alternative to those who are treatment 
resistant, treatment intolerant or treatment sceptical 
to conventional therapy for whatever reason. The 
technology also works fast and synergistically with other 
established treatments or therapies. This is important 
in potentially life threatening scenarios. Finally, the side 
effect profile is very good indeed and there are very few 
contraindications. Although still in their infancy, other 
future therapies look promising.
Figure 2: The position of the rTMS treatment coil on the scalp
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